[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562590":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":78,"centralContacts":85,"locations":92,"responsibleParty":231,"collaborators":233,"id":236,"slug":37,"hasResults":237,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":237,"sex":243,"minAge":244,"maxAge":37,"enrollmentInfo":245,"targetDuration":37,"studyType":248,"phases":249,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":95,"whyStopped":37,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":267},{"fullName":5,"class":6},"Université de Sherbrooke","OTHER",[8,16,25],{"label":9,"type":6,"description":10,"interventionNames":11},"Vasopressor","Participants will receive vasopressor(s) and their mean arterial pressure will be titrated according to the group they are randomized to (group 1: 56-60 mmHg; group 2: 61-65 mmHg; group 3: 66-70 mmHg; group 4: 71-75 mmHg). Physicians will have the liberty of restricting the randomization to at least 2 contiguous ranges",[12,13,14,15],"Drug: 1- Vasopressor - Mean arterial pressure 56-60","Drug: 2- Vasopressor - Mean arterial pressure 61-65","Drug: 3- Vasopressor - Mean arterial pressure 66-70","Drug: 4- Vasopressor - Mean arterial pressure 71-75",{"label":17,"type":6,"description":18,"interventionNames":19},"Platelet","Thrombocytopenic intensive care unit (ICU) patients (platelet count \\\u003C50×109\u002FL) with a planned low-moderate bleeding-risk procedure will be randomized to one of five equally spaced platelet thresholds (less than 10 x 109\u002FL, less than 20 x 109\u002FL, less than 30 x 109\u002FL, less than 40 x 109\u002FL, less than 50 X 109\u002FL) below which they will receive prophylactic platelet transfusions before any low-moderate bleeding-risk procedure occurring during the ICU episode up to ICU day 90. Once randomized, the clinical team will administer a platelet transfusion according to the assigned threshold and the most recent platelet count at the time of the planned procedure.",[20,21,22,23,24],"Other: 1- Platelet less than 10 x 109\u002FL","Other: 2- Platelet less than 20 x 109\u002FL","Other: 3- Platelet less than 30 x 109\u002FL","Other: 4- Platelet less than 40 x 109\u002FL","Other: 5- Platelet less than 50 x 109\u002FL",{"label":26,"type":6,"description":27,"interventionNames":28},"Nutrition","The intervention is bolus feeding (given 3 times a day to meet nutritional targets) with formula type left to the discretion of the precribing team. With 2 hours between each \"feed\".\n\nThe control is continuous feeding (over 24-hour period) with formula type left to the discretion of the prescribing team, which is the current standard of care.",[29,30],"Other: Enteral nutrition - Boluses","Other: Enteral nutrition - Continuous",[32,38,42,46,50,54,58,62,66,70,74],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","1- Vasopressor - Mean arterial pressure 56-60","Vasopressor(s) will be titrated according to 56-60 range.",[9],null,{"type":33,"name":39,"description":40,"armGroupLabels":41,"otherNames":37},"2- Vasopressor - Mean arterial pressure 61-65","Vasopressor(s) will be titrated according to 61-65 range.",[9],{"type":33,"name":43,"description":44,"armGroupLabels":45,"otherNames":37},"3- Vasopressor - Mean arterial pressure 66-70","Vasopressor(s) will be titrated according to 66-70 range.",[9],{"type":33,"name":47,"description":48,"armGroupLabels":49,"otherNames":37},"4- Vasopressor - Mean arterial pressure 71-75","Vasopressor(s) will be titrated according to 71-75 range.",[9],{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":37},"1- Platelet less than 10 x 109\u002FL","Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 10 x 109\u002FL at the time of the planned procedure.",[17],{"type":6,"name":55,"description":56,"armGroupLabels":57,"otherNames":37},"2- Platelet less than 20 x 109\u002FL","Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 20 x 109\u002FL at the time of the planned procedure.",[17],{"type":6,"name":59,"description":60,"armGroupLabels":61,"otherNames":37},"3- Platelet less than 30 x 109\u002FL","Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 30 x 109\u002FL at the time of the planned procedure.",[17],{"type":6,"name":63,"description":64,"armGroupLabels":65,"otherNames":37},"4- Platelet less than 40 x 109\u002FL","Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 40 x 109\u002FL at the time of the planned procedure.",[17],{"type":6,"name":67,"description":68,"armGroupLabels":69,"otherNames":37},"5- Platelet less than 50 x 109\u002FL","Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 50 x 109\u002FL at the time of the planned procedure.",[17],{"type":6,"name":71,"description":72,"armGroupLabels":73,"otherNames":37},"Enteral nutrition - Boluses","Given 3 times a day.",[26],{"type":6,"name":75,"description":76,"armGroupLabels":77,"otherNames":37},"Enteral nutrition - Continuous","Given over 24-hour period",[26],[79,82],{"name":80,"affiliation":5,"role":81},"Francois Lamontagne, MD, MSc","PRINCIPAL_INVESTIGATOR",{"name":83,"affiliation":84,"role":81},"Neill Adhikari, MDCM, MSc","Sunnybrook Research Institute",[86],{"name":87,"role":88,"phone":89,"phoneExt":90,"email":91},"Marie-Helene Masse, RRT, MSc","CONTACT","1-819-346-1110","14173","marie-helene.masse3@usherbrooke.ca",[93,113,129,145,160,176,194,212,222],{"facility":94,"status":95,"city":96,"state":97,"zip":98,"country":99,"cosmosGeoPoint":100,"geoPoint":105,"contacts":106},"Hamilton Health Sciences - Juravinski Hospital","RECRUITING","Hamilton","Ontario","L8V 1C3","Canada",{"type":101,"coordinates":102},"Point",[103,104],-79.84963,43.25011,{"lat":104,"lon":103},[107,111],{"name":108,"role":88,"phone":109,"phoneExt":37,"email":110},"Tina Millen","905-521-2100","millent@mcmaster.ca",{"name":112,"role":81,"phone":37,"phoneExt":37,"email":37},"Bram Rochwerg",{"facility":114,"status":95,"city":115,"state":97,"zip":116,"country":99,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"The Ottawa Hospital","Ottawa","K1H 8L6",{"type":101,"coordinates":118},[119,120],-75.69812,45.41117,{"lat":120,"lon":119},[123,127],{"name":124,"role":88,"phone":125,"phoneExt":37,"email":126},"Irene Watpool","613-737-8724","iwatpool@ohri.ca",{"name":128,"role":81,"phone":37,"phoneExt":37,"email":37},"Alexandre Tran",{"facility":130,"status":95,"city":131,"state":97,"zip":132,"country":99,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Scarborough Health Network","Scarborough Village","M1P 2V5",{"type":101,"coordinates":134},[135,136],-79.22124,43.73899,{"lat":136,"lon":135},[139,143],{"name":140,"role":88,"phone":141,"phoneExt":37,"email":142},"Joshua Craig","416-438-2911","jcraig@shn.ca",{"name":144,"role":81,"phone":37,"phoneExt":37,"email":37},"Christopher Yarnell",{"facility":146,"status":95,"city":147,"state":97,"zip":148,"country":99,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Niagara Health","St. Catharines","L2S 0A9",{"type":101,"coordinates":150},[151,152],-79.24267,43.17126,{"lat":152,"lon":151},[155,159],{"name":156,"role":88,"phone":157,"phoneExt":37,"email":158},"Jennifer Tsang","905-684-7271","jennifer.tsang@mail.utoronto.ca",{"name":156,"role":81,"phone":37,"phoneExt":37,"email":37},{"facility":161,"status":95,"city":162,"state":97,"zip":163,"country":99,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Sunnybrook Health Sciences Centre","Toronto","M4N 3M5",{"type":101,"coordinates":165},[166,167],-79.39864,43.70643,{"lat":167,"lon":166},[170,174],{"name":171,"role":88,"phone":172,"phoneExt":37,"email":173},"Nicole Marinoff","416-480-4522","Nicole.Marinoff@sunnybrook.ca",{"name":175,"role":81,"phone":37,"phoneExt":37,"email":37},"Neill Adhikari",{"facility":177,"status":95,"city":178,"state":179,"zip":180,"country":99,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Centre hospitalier de l'Université de Montréal (CHUM)","Montreal","Quebec","H2X 0C1",{"type":101,"coordinates":182},[183,184],-73.58781,45.50884,{"lat":184,"lon":183},[187,192],{"name":188,"role":88,"phone":189,"phoneExt":190,"email":191},"Melissa Gagnon-Hamelin","514 890-8000","31750","melissa.gagnon-hamelin.chum@ssss.gouv.qc.ca",{"name":193,"role":81,"phone":37,"phoneExt":37,"email":37},"Francois-Martin Carrier",{"facility":195,"status":95,"city":196,"state":179,"zip":197,"country":99,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"CIUSSS de l'Estrie - CHUS","Sherbrooke","J1H 5N4",{"type":101,"coordinates":199},[200,201],-71.89908,45.40008,{"lat":201,"lon":200},[204,206,210],{"name":87,"role":88,"phone":205,"phoneExt":90,"email":91},"819-346-1110",{"name":207,"role":88,"phone":205,"phoneExt":208,"email":209},"Monica Sean, PhD","14266","monica.sean@usherbrooke.ca",{"name":211,"role":81,"phone":37,"phoneExt":37,"email":37},"Francois Lamontagne",{"facility":213,"status":214,"city":215,"state":37,"zip":37,"country":216,"cosmosGeoPoint":217,"geoPoint":221,"contacts":37},"Auckland City Hospital","NOT_YET_RECRUITING","Auckland","New Zealand",{"type":101,"coordinates":218},[219,220],174.76349,-36.84853,{"lat":220,"lon":219},{"facility":223,"status":214,"city":224,"state":37,"zip":37,"country":225,"cosmosGeoPoint":226,"geoPoint":230,"contacts":37},"Intensive Care National Audit and Research Centre (coordinating centre for sites in UK. Sites to be determined)","London","United Kingdom",{"type":101,"coordinates":227},[228,229],-0.12574,51.50853,{"lat":229,"lon":228},{"type":232,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[234],{"name":235,"class":6},"Hamilton Health Sciences Corporation","100562590",false,"NCT06605144","Canadian Critical Care Comparative Effectiveness Platform","Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en Soins Critiques (CEPEC)","CEPEC","VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain.\n\nInclusion criteria:\n\n1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care;\n2. MAP \\\u003C75 mmHg at any point;\n3. Patient expected to be in the ICU for \\>24 hours.\n\nExclusion criteria:\n\n1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain;\n2. Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure);\n3. Acute subarachnoid hemorrhage (within 21 days);\n4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia);\n5. Lung, heart, liver, kidney transplant recipient (within 7 days);\n6. Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD);\n7. More than 24 hours since meeting inclusion criteria in the ICU;\n8. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial.\n\nPLATELET DOMAIN\n\nInclusion criteria:\n\n1. Adult patients (age ≥18 years) admitted to the ICU;\n2. Latest platelet count in this hospital admission \\\u003C50×109\u002FL;\n3. Planned to undergo a specified low-moderate bleeding risk invasive procedure.\n\nExclusion criteria:\n\n1. Ongoing major hemorrhage requiring blood products and\u002For surgical\u002F radiological intervention;\n2. Intracranial hemorrhage within prior 72 hours;\n3. Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects);\n4. Known advance decision of refusing blood\u002Fblood component transfusions;\n5. Acute promyelocytic leukemia (APML);\n6. Death perceived as imminent or admission for palliation;\n7. Previously randomized into the CEPEC Platelet Domain or the T4P Trial;\n8. Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours.\n\nNUTRITION DOMAIN\n\nInclusion criteria:\n\n1. Critically ill patients ≥18 years of age;\n2. Are invasively mechanically ventilated (including endotracheal tube or tracheostomy);\n3. Orogastric\u002Fnasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement);\n4. Treating team has started or has the intention of providing enteral nutrition.\n\nExclusion criteria:\n\n1. Patients who have had gastrointestinal (GI) surgery; in the last 3 months and deemed not ready to receive possible bolus nutrition;\n2. Bowel obstruction or ischemia; active;\n3. Has a post-pyloric small bowel feeding tube;\n4. Active GI bleeding;\n5. Patient who is chronically receiving enteral nutrition.","ALL","18 Years",{"count":246,"type":247},5500,"ESTIMATED","INTERVENTIONAL",[250],"PHASE3","The Canadian Critical Care Comparative Effectiveness Platform(e) d'Évaluation Clinique Comparée en soins Critiques (CEPEC) is an international multi-centered randomized adaptive platform clinical trial. CEPEC will evaluate supportive care interventions that are used routinely in intensive care units throughout the world.",[253,9,17,26],"Intensive Care Unit ICU",[255,256,9,17,257],"ICU","Adaptive platform trial","Enteral nutrition","2026-06-25",{"date":260,"type":261},"2026-06-30","ACTUAL",{"date":263,"type":261},"2025-03-23",{"date":265,"type":247},"2030-06-30",{"name":5,"class":6},9]